Avalo Therapeutics, Inc. (CERC) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sonoma Pharmaceuticals, Inc.

Plus Therapeutics, Inc.

180 Life Sciences Corp.

Avalo Therapeutics, Inc.

Palisade Bio, Inc.

ABVC BioPharma, Inc.

Dermata Therapeutics, Inc.

Adial Pharmaceuticals, Inc.

Panbela Therapeutics, Inc.

Baudax Bio, Inc.

Aptorum Group Ltd.

Why is Avalo Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Avalo Therapeutics, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Avalo Therapeutics, Inc.

208.82%

0.38

92.30%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-61.06%

EBIT Growth (5y)

-14.47%

EBIT to Interest (avg)

-31.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

-0.01

Tax Ratio

0.16%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

89.45%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.81

EV to EBIT

-3.02

EV to EBITDA

-3.04

EV to Capital Employed

-17.05

EV to Sales

220.55

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-82.77%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -38.99 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

-23What is not working for the Company

NET SALES(HY)

At USD 0.06 MM has Grown at -69.27%

OPERATING CASH FLOW(Y)

Lowest at USD -59.69 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 0 times

OPERATING PROFIT(Q)

Lowest at USD -20.88 MM

PRE-TAX PROFIT(Q)

Lowest at USD -20.1 MM

NET PROFIT(Q)

Lowest at USD -20.11 MM

Here's what is working for Avalo Therapeutics, Inc.

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Avalo Therapeutics, Inc.

Net Sales

At USD 0.06 MM has Grown at -69.27%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -59.69 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -20.88 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -20.1 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -20.11 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debtors Turnover Ratio

Lowest at 0 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio